Waverley Pharma Inc (V:WAVE) — Market Cap & Net Worth
Market Cap & Net Worth: Waverley Pharma Inc (WAVE)
Waverley Pharma Inc (V:WAVE) has a market capitalization of $540.00K (CA$746.49K) as of July 13, 2026. Listed on the V stock exchange, this Canada-based company holds position #30912 globally and #1642 in its home market, demonstrating a 150.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Waverley Pharma Inc's stock price CA$0.03 by its total outstanding shares 54000000 (54.00 Million). Review Waverley Pharma Inc (WAVE) FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
Waverley Pharma Inc Market Cap History: 2017 to 2026
Waverley Pharma Inc's market capitalization history from 2017 to 2026. Data shows change from $17.58 Million to $976.57K (-22.24% CAGR).
Waverley Pharma Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Waverley Pharma Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.82x
Waverley Pharma Inc's market cap is 0.82 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2018 | $10.94 Million | $223.40K | -$1.42 Million | 48.96x | N/A |
| 2019 | $3.91 Million | $1.16 Million | -$1.21 Million | 3.38x | N/A |
| 2020 | $4.88 Million | $1.38 Million | -$705.76K | 3.55x | N/A |
| 2021 | $3.13 Million | $1.75 Million | -$796.51K | 1.78x | N/A |
| 2022 | $1.17 Million | $1.25 Million | -$664.08K | 0.94x | N/A |
| 2023 | $976.57K | $412.09K | -$2.22 Million | 2.37x | N/A |
| 2024 | $390.63K | $475.37K | -$947.08K | 0.82x | N/A |
Competitor Companies of WAVE by Market Capitalization
Companies near Waverley Pharma Inc in the global market cap rankings as of July 13, 2026.
Key companies related to Waverley Pharma Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #429 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #549 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #567 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $485.39 |
| #429 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $664.52 |
| #549 | Argen-X | BR:ARGX | $49.55 Billion | €763.80 |
| #567 | UCB SA | BR:UCB | $47.34 Billion | €237.10 |
Waverley Pharma Inc Historical Marketcap From 2017 to 2026
Between 2017 and today, Waverley Pharma Inc's market cap moved from $17.58 Million to $ 976.57K, with a yearly change of -22.24%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CA$976.57K | +25.00% |
| 2025 | CA$781.26K | +100.00% |
| 2024 | CA$390.63K | -60.00% |
| 2023 | CA$976.57K | -16.67% |
| 2022 | CA$1.17 Million | -62.50% |
| 2021 | CA$3.13 Million | -36.00% |
| 2020 | CA$4.88 Million | +25.00% |
| 2019 | CA$3.91 Million | -64.29% |
| 2018 | CA$10.94 Million | -37.78% |
| 2017 | CA$17.58 Million | -- |
End of Day Market Cap According to Different Sources
On Jul 12th, 2026 the market cap of Waverley Pharma Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $540.00K USD |
| MoneyControl | $540.00K USD |
| MarketWatch | $540.00K USD |
| marketcap.company | $540.00K USD |
| Reuters | $540.00K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Waverley Pharma Inc
Waverley Pharma Inc., a biopharmaceutical company, researches, develops, and commercializes oncology therapeutics in the United Kingdom. The company develops poly ADP-ribose polymerase-1 (PARP-1) inhibitors for cancer treatment. It also operates a retail pharmacy in the United States. Waverley Pharma Inc. was founded in 2014 and is headquartered in Winnipeg, Canada.